Neuro

SunSpear Games Announces Kickstarter Alpha Event for IMMORTAL: Gates of Pyre

Retrieved on: 
Thursday, May 12, 2022
StarCraft, Aegon Targaryen, Pig, The Elder Scrolls V: Skyrim, Kickstarter, Immortal, Strategy, Neuro, PDT, PC, Person, AAA, Discord, CEO, Video game, Entertainment

ASHLAND, Ore., May 12, 2022 /PRNewswire/ -- SunSpear Games, developer of the highly anticipated IMMORTAL: Gates of Pyre Battle Strategy game, announced today their Kickstarter Alpha Event.

Key Points: 
  • ASHLAND, Ore., May 12, 2022 /PRNewswire/ -- SunSpear Games, developer of the highly anticipated IMMORTAL: Gates of Pyre Battle Strategy game, announced today their Kickstarter Alpha Event.
  • To mark the Kickstarter Alpha, SunSpear Games will hold an Alpha Launch Party Event Weekend to include influential content creators, starting with PiG and Livibee at 5 pm PDT and 8 pm PDT Friday, May 13th, respectively.
  • "We're proud to be delivering on the promise to our Kickstarter backers with their first experience playing IMMORTAL: Gates of Pyre," said Kevin Wagner, CEO of SunSpear Games.
  • SunSpear Games, Inc. is a video game development studio with over 35 employees working on its first AAA title, IMMORTAL: Gates of Pyre.

Curative Biotechnology, Inc. Names Cary Sucoff to Board of Directors

Retrieved on: 
Thursday, May 12, 2022
Binghamton University, Company, Bar, New England Law Boston, Past, CD56, Committee on Finance, Board of directors, Neuro, Historical annual reformulations of the influenza vaccine, BOCA, Infection, City of London Finance Committee, Vaccine, OTC, OTC Markets Group, Judgement, Review, The National Law Review, Therapy, Degenerative disease, Comp, IMAC, Rabies, AMD, Securities Act of 1933, Securities Exchange Act of 1934, Industry, Trustee, Director, Audit, Glaucoma, Compliance, Board, Metformin, Technology, Neoplasm, Law review, Movement, Schizophrenia, Pharmaceutical industry, Financial adviser, Fine chemical, Medical device, Biotechnology, Walmart, Glioblastoma, Tel Aviv University

BOCA RATON, Fla., May 12, 2022 /PRNewswire/ -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Cary Sucoff has joined its Board of Directors as an independent director.  With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies. Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees.

Key Points: 
  • BOCA RATON, Fla., May 12, 2022 /PRNewswire/ -- Curative Biotechnology Inc. (OTC: CUBT) ("Curative Biotech" or the "Company"), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Cary Sucoff has joined its Board of Directors as an independent director.
  • Since 2011, Mr. Sucoff has owned and operated Equity Source Partners LLC, an advisory and consulting firm.
  • In addition, Mr. Sucoff currently serves as an advisor to:
    Sapience Therapeutics, Inc. - a Phase 1/2 Biotech company focusing on Glioblastoma.
  • Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases.

Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors

Retrieved on: 
Thursday, May 12, 2022
Past, CD56, Committee on Finance, Neuro, City of London Finance Committee, OTC Markets Group, Review, Director, Audit, Securities Act of 1933, New England Law Boston, Movement, Schizophrenia, Binghamton University, Judgement, Therapy, Degenerative disease, Rabies, Board, Neoplasm, GLOBE, Bar, Company, Historical annual reformulations of the influenza vaccine, Infection, Vaccine, Trustee, Law review, Securities Exchange Act of 1934, Board of directors, OTC, Harvard Law Review, Comp, AMD, Industry, Glaucoma, Compliance, Metformin, Technology, Pharmaceutical industry, Financial adviser, Fine chemical, Medical device, Walmart, Glioblastoma, Tel Aviv University, Biotechnology

Boca Raton, FL, May 12, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Cary Sucoff has joined its Board of Directors as an independent director. With over 35 years of legal and securities industry experience, Cary Sucoff has participated in the financing of over one hundred public and private companies and is currently on the boards of, or an advisor to, six healthcare and biotechnology companies. Mr. Sucoff is an expert in legal, compliance, corporate strategy, and capital markets and has chaired or sat on audit, compensation, nominating/governance, and special committees.

Key Points: 
  • Boca Raton, FL, May 12, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (Curative Biotech or the Company), a development-stage biomedical company focused on novel treatments for rare diseases and conditions, announced today that Cary Sucoff has joined its Board of Directors as an independent director.
  • Since 2011, Mr. Sucoff has owned and operated Equity Source Partners LLC, an advisory and consulting firm.
  • In addition, Mr. Sucoff currently serves as an advisor to:
    Sapience Therapeutics, Inc. - a Phase 1/2 Biotech company focusing on Glioblastoma.
  • Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases.

Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month

Retrieved on: 
Thursday, May 12, 2022
GBM, Microbiology, Brain tumor, KOL, Doctor of Philosophy, Johns Hopkins School of Medicine, Survival, Oncology, Kennedy Krieger Institute, Neuro, Webcast, Patient, Brain, A.I, NASDAQ, ADC, Internal medicine, Neurology, Glioma, Sidney Kimmel, Johns Hopkins, University, Caregiver, Research, Awareness, Johns Hopkins Bayview Medical Center, BBB, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Probability, Glioblastoma, Berlin, Division, Brain Tumor Awareness Month, Machine learning, Therapy, Case Western Reserve University, Neuroscience, Fine chemical, Medical imaging, Medicine, Lantern

The webinar will focus on glioblastoma multiforme (GBM) and the potential of Lantern's drug candidate LP-184 for GBM as well as other brain cancers.

Key Points: 
  • The webinar will focus on glioblastoma multiforme (GBM) and the potential of Lantern's drug candidate LP-184 for GBM as well as other brain cancers.
  • The webcast will feature discussions by two leading experts in GBM and brain cancer treatment and research: John Laterra, M.D., Ph.D. and Matthias Holdhoff, M.D., Ph.D.
  • Dr. Holdhoff completed his residency in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital.
  • Lantern is currently developing four drug candidates and an ADC program across ninedisclosed tumor targets, including two phase 2 programs.

Pipeline Therapeutics to Present at Multiple Investor Conferences in May 2022

Retrieved on: 
Wednesday, May 11, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, FDA, CNS, IND, Company, LinkedIn, Therapy, MS, Program, Neuro, Pharmaceutical industry

Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will present at the following investor conferences:

Key Points: 
  • Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that company management will present at the following investor conferences:
    Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair.
  • The Company has a broad pipeline of programs to address CNS and neuro-otology conditions.
  • Its flagship program, PIPE-307, has completed a Phase 1 clinical trial in healthy volunteers and has received IND clearance from the FDA to initiate a Phase 1b/2a trial in relapsing-remitting MS patients.
  • For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

InvestmentPitch Media Video Discusses FSD Pharma, a Life Sciences Holding Company, and the Closing of its Sale of Non-Core Assets for $16.4 million

Retrieved on: 
Wednesday, May 11, 2022
Share repurchase, Interim, Neuro, NASDAQ, Myelin, GLOBE, US, Multiple sclerosis, CSE, Inflammation, Suggestion, Sale, Canadian Securities Exchange, News, Awareness, Risk, Major depressive disorder, Bank, Pharmaceutical industry

If these links are not enabled, please visit www.InvestmentPitch.com and enter FSD Pharma in the search box.

Key Points: 
  • If these links are not enabled, please visit www.InvestmentPitch.com and enter FSD Pharma in the search box.
  • The company has sold its former cannabis processing facility, located in Coburg, Ontario, which it acquired for $5.5 million in November 2017.
  • FSD Pharma has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format.
  • Investmentpitch Media Ltd makes no warranties or undertakings as to the accuracy or completeness of this information.

Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event

Retrieved on: 
Monday, May 9, 2022
Health, Genetics, U.S. Securities and Exchange Commission, Form 10-K, NPC2, NPC, NPC1, Expanded access, Brain, CYTH, Neuro, Nasdaq, Priority review, UCSF Benioff Children's Hospital, Company, Neoplasm, Physician, Patient advocacy, Death, Patient, Doctor of Philosophy, Pediatrics, American Society of Pediatric Hematology/Oncology, Glycogen storage disease, Organization, Lung, Risk, Spinal cord, Acute lymphoblastic leukemia, Hospital, Protocol, MD, Security (finance), Investor, Global, Cholesterol, Science, Education, Disease, Liver, Lists of diseases, Virtual, Spleen, Transport, Cell, Children's Hospital Oakland, Niemann–Pick disease, Therapy, Pharmaceutical industry, EU

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it will participate in the Virtual Investor Niemann-Pick Disease Type C (NPC) Spotlight event on Monday, May 16, 2022 at 2:00 PM ET.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced it will participate in the Virtual Investor Niemann-Pick Disease Type C (NPC) Spotlight event on Monday, May 16, 2022 at 2:00 PM ET.
  • Her academic interests include tumors of the brain and spinal cord, relapsed acute lymphoblastic leukemia, and lysosomal storage diseases including Niemann Pick Type C disease.
  • Cyclo Therapeutics received Orphan Drug Designation for Trappsol Cyclo to treat NPC1 in both the U.S. and EU and Fast Track and Rare Pediatric Disease Designations in the U.S.
  • Cyclo Therapeutics, Inc. is a late clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease.

Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain

Retrieved on: 
Monday, May 9, 2022
Technology, Biotechnology, Nanotechnology, Alternative Medicine, Health, Pharmaceutical, Mental Health, Research, Medical Devices, Software, Hardware, Science, Data Management, Clinical Trials, Neuro, United Kingdom, COVID-19, NYSE American, Psilocybin, Forward-looking statement, Brain, U.S. Securities and Exchange Commission, Company, NYSE, Food and Drug Administration, Engineering, Food, Safety, Time, NEO, Patient, Partnership, Risk, FDA, Day, Therapy, Data, Efficiency, Disease, Investigational New Drug, View, EDGAR, Health Canada, Consciousness, Goal, Technology, News, Research, Growth, Multimedia, Medical imaging, Pharmaceutical industry, Ketamine, Flow, Kernel, Technology, Biotechnology, Nanotechnology, Alternative Medicine, Health, Pharmaceutical, Mental Health, Research, Medical Devices, Software, Hardware, Science, Data Management, Clinical Trials

The piloting was conducted to ensure the efficiency of the feasibility study design.

Key Points: 
  • The piloting was conducted to ensure the efficiency of the feasibility study design.
  • Participants in the pilot received either a low dose of ketamine and/or a placebo while wearing the Flow headset.
  • Kernel Flow is a groundbreaking neuroimaging technology that enables rigorous characterization and quantification of physiological processes in the human brain.
  • On March 31, 2022, Cybin and Kernel announced the initiation of the feasibility study and enrollment is ongoing.

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022
D, HBF, KOL, EHA, Neuro, MRI, Nasdaq, Thalassemia, IND, MDA, GLOBE, European Hematology Association, Sickle cell disease, Facioscapulohumeral muscular dystrophy, PGIC, Safety, Research, Hemoglobinopathy, Patient, Quality of life, Webcast, Ascending limb of loop of Henle, Conference call, Investor relations, Losmapimod, Initiate, American Academy, RWS, Investigational New Drug, Episcopal conference, Conference, HIV disease progression rates, Growth, Quality, Therapy, MFI, Pharmaceutical industry, Video game, EU, REACH, FSHD

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2022.

Key Points: 
  • (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2022.
  • Additionally, we plan to begin dosing patients in REACH, our Phase 3 trial of losmapimod in FSHD, in the second quarter.
  • Open next dose cohort in Phase 1b trial in people with sickle cell disease in the second quarter of 2022.
  • ET to discuss the Companys first quarter 2022 recent business highlights and financial results.

National brands join forces with Team RWB to support veterans during Military Appreciation Month

Retrieved on: 
Thursday, May 5, 2022
White, Fort Bragg, Neuro, Woman, Blue and White, Partnership, Yuengling, Program, Stars & Stripes, Veteran, Health, Compression, CEO, Team, RWB, Man, Multimedia, Interior design, Toy, Online shopping

ATLANTA, May 5, 2022 /PRNewswire/ -- In honor of Military Appreciation Month, eight national brands are partnering with Team Red, White & Blue (Team RWB), a nonprofit organization forging America's leading health and wellness community for veterans.

Key Points: 
  • ATLANTA, May 5, 2022 /PRNewswire/ -- In honor of Military Appreciation Month, eight national brands are partnering with Team Red, White & Blue (Team RWB), a nonprofit organization forging America's leading health and wellness community for veterans.
  • National brands join forces with Team RWB to support veterans during Military Appreciation Month.
  • "The SheerID platform makes it easy and secure for brands to recognize members of the military with special offers and rewards.
  • Humana Military: Team RWB will be joining Humana Military 's Military Health and Resilience Collective Impact Project alongside the Military Family Advisory Network and Blue Star Families, designed uniquely to provide holistic support to military families.